Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01279
|
|||||
| Drug Name |
Phenprocoumon
|
|||||
| Synonyms |
2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one; Falithiom; Falithrom; Falithrom (TN); Fencumar; Fenprocoumona; Fenprocoumona [INN-Spanish]; Fenprocumon; Fenprocumone; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Liquamar; Liquamar (TN); Marcoumar; Marcoumar (TN); Marcumar; Marcumar (TN); Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; Phenprocoumone; Phenprocoumone [INN-French]; Phenprocoumonum; Phenprocoumonum [INN-Latin]; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Ro 1-4849; Roche Brand of Phenprocoumon; U29342; Worwag Brand of Phenprocoumon
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Thrombosis [ICD11: BD71.4, BD72] | Approved | [1] | |||
| Pulmonary embolism [ICD11: BB00] | Approved | [1] | ||||
| Therapeutic Class |
Anticoagulants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H16O3
|
|||||
| Canonical SMILES |
CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
|
|||||
| InChI |
InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
|
|||||
| InChIKey |
DQDAYGNAKTZFIW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 435-97-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 280.3 | Topological Polar Surface Area | 46.5 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
612021
, 7845703
, 7980293
, 8030662
, 10522853
, 14848717
, 29228465
, 42684251
, 46506423
, 47207126
, 47815891
, 48416418
, 49956264
, 56394971
, 57309600
, 57325861
, 76965160
, 93302774
, 103179879
, 103950577
, 104253508
, 104321863
, 106673762
, 125823525
, 126658557
, 127770897
, 134338056
, 134974499
, 135692445
, 137126448
, 137239431
, 142971044
, 160964285
, 162011455
, 162224643
, 162652374
, 163418248
, 164042860
, 174529392
, 176262013
, 178103445
, 179326620
, 184545898
, 186014484
, 198993025
, 219400682
, 223670210
, 223705291
, 226427577
, 227840593
|
|||||
| ChEBI ID |
ChEBI:50438
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Phenprocoumon was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.